TCS-OX2-29

TCS-OX2-29
(IUPAC) ime
	(2S)-1-(3,4-Dihydro- 6,7-dimethoxy- 2(1H)-isoquinolinyl)- 3,3-dimethyl- 2-[(4-pyridinylmethyl)amino]- 1-butanone
Klinički podaci
Identifikatori
CAS broj	372523-75-6
ATC kod	?
PubChem	10408514
Hemijski podaci
Formula	C23H31N3O3
Mol. masa	397.509 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3 ; Key: COFVZFLCAOUMJT-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

TCS-OX2-29 je lek koji je nepeptidni selektivni antagonist oreksinskog receptora tipa OX₂. Njegova IC₅₀ vrednost je 40 nM. On je oko 250 puta selektivniji za OX₂ nego OX₁ receptor.^[3] Za oreksinske antagoniste se smatra da će naći upotrebu u lečenju insomnije. Selektivni antagonisti poput TCS-OX2-29 potencijalno pružaju specifičnije dejstvo nego nesektivni oreksinski antagonisti, kao što je almoreksant.^[4]

Vidi još[uredi | uredi kod]

Oreksinski receptor 2

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hirose M, Egashira S, Goto Y, et al. (December 2003). „N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist”. Bioorganic & Medicinal Chemistry Letters 13 (24): 4497–9. PMID 14643355. Pristupljeno 2011-04-24.
↑ Roecker AJ, Coleman PJ (2008). „Orexin receptor antagonists: medicinal chemistry and therapeutic potential”. Current Topics in Medicinal Chemistry 8 (11): 977–87. PMID 18673167. Pristupljeno 2011-04-24. ^{[mrtav link]}

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

Šablon:Neuropeptidni ligandi

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid14643355-3] Hirose M, Egashira S, Goto Y, et al. (December 2003). „N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist”. Bioorganic & Medicinal Chemistry Letters 13 (24): 4497–9. PMID 14643355. Pristupljeno 2011-04-24.

[pmid18673167-4] Roecker AJ, Coleman PJ (2008). „Orexin receptor antagonists: medicinal chemistry and therapeutic potential”. Current Topics in Medicinal Chemistry 8 (11): 977–87. PMID 18673167. Pristupljeno 2011-04-24. ^{[mrtav link]}

[1]

[2]

[3]

[4]

TCS-OX2-29

Vidi još[uredi | uredi kod]

Reference[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga